...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers.
【24h】

Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers.

机译:通过一系列microRNA标记物早期检测痰中的肺腺癌。

获取原文
获取原文并翻译 | 示例

摘要

Adenocarcinoma is the most common type of lung cancer, the leading cause of cancer deaths in the world. Early detection is the key to improve the survival of lung adenocarcinoma patients. We have previously shown that microRNAs (miRNAs) were stably present in sputum and could be applied to diagnosis of lung cancer. The aim of our study was to develop a panel of miRNAs that can be used as highly sensitive and specific sputum markers for early detection of lung adenocarcinoma. Our study contained 3 phases: (i) marker discovery using miRNA profiling on paired normal and tumor lung tissues from 20 patients with lung adenocarcinoma; (ii) marker optimization by real-time reverse transcription-quantitative polymerase chain reaction on sputum of a case-control cohort consisting of 36 cancer patients and 36 health individuals and (iii) validation on an independent set of 64 lung cancer patients and 58 cancer-free subjects. From the surgical tissues, 7 miRNAs with significantly altered expression were identified, of which 4 sputum samples of the case-control cohort, 4 (miR-21, miR-486, miR-375 and miR-200b) of the 7 miRNAs were selected, which in combination produced the best prediction in distinguishing lung adenocarcinoma patients from normal subjects with 80.6% sensitivity and 91.7% specificity. Validation of the marker panel in the independent populations confirmed the sensitivity and specificity that provided a significant improvement over any single one alone. The sputum markers demonstrated the potential of translation to laboratory settings for improving the early detection of lung adenocarcinoma.
机译:腺癌是最常见的肺癌类型,是世界上导致癌症死亡的主要原因。早期发现是提高肺腺癌患者生存率的关键。先前我们已经证明,微小RNA(miRNA)稳定存在于痰液中,可用于诊断肺癌。我们研究的目的是开发一组miRNA,可用作早期检测肺腺癌的高灵敏度和特异性痰液标记物。我们的研究包括三个阶段:(i)在20例肺腺癌患者的正常和肿瘤肺组织配对中使用miRNA分析进行标记发现; (ii)通过实时逆转录-定量聚合酶链反应对由36名癌症患者和36名健康个体组成的病例对照队列的痰液进行标记优化,以及(iii)对64名肺癌患者和58名癌症患者进行独立验证-免费科目。从手术组织中,鉴定出7个表达明显改变的miRNA,其中有4个病例对照人群的痰标本,选择了7个miRNA中的4个(miR-21,miR-486,miR-375和miR-200b)。 ,结合敏感性和特异性分别为80.6%和91.7%的结果,可以最好地预测将肺腺癌患者与正常人区分开。在独立人群中对标志物组的验证证实了其敏感性和特异性,与单独的任何一个相比,其显着改善。痰液标记物显示了翻译成实验室设置的潜力,可改善肺腺癌的早期检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号